Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature

Clin Genitourin Cancer. 2019 Aug;17(4):e721-e723. doi: 10.1016/j.clgc.2019.02.012. Epub 2019 Mar 15.

Authors

Manon de Vries-Brilland¹, Baptiste Sionneau¹, Caroline Dutriaux², Jean-Yves Blay³, Alain Ravaud⁴, Marine Gross-Goupil⁵

Affiliations

¹ Department of Medical Oncology, Saint-André Hospital, Bordeaux University Hospital, Bordeaux, France.
² Department of Dermatology, Saint-André Hospital, Bordeaux University Hospital, Bordeaux, France.
³ Department of Adult Medical Oncology, Leon Berard Center, Lyon, France.
⁴ Department of Medical Oncology, Saint-André Hospital, Bordeaux University Hospital, Bordeaux, France; Bordeaux University, Bordeaux, France.
⁵ Department of Medical Oncology, Saint-André Hospital, Bordeaux University Hospital, Bordeaux, France. Electronic address: marine.gross-goupil@chu-bordeaux.fr.

PMID: 31109800
DOI: 10.1016/j.clgc.2019.02.012

No abstract available

Keywords: BRAF V600E mutation; BRAF inhibitor; Dabrafenib; Nephroblastoma; Wilms Tumor.

Publication types

Case Reports
Review

MeSH terms

Humans
Imidazoles / administration & dosage
Imidazoles / pharmacology
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / genetics
Liver Neoplasms / drug therapy*
Liver Neoplasms / secondary
Lung Neoplasms / drug therapy*
Lung Neoplasms / secondary
Lymphatic Metastasis
Middle Aged
Mutation
Oximes / administration & dosage
Oximes / pharmacology
Protein Kinase Inhibitors / administration & dosage*
Protein Kinase Inhibitors / pharmacology
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics
Treatment Outcome
Vemurafenib / administration & dosage
Vemurafenib / pharmacology
Wilms Tumor / drug therapy*
Wilms Tumor / genetics

Substances

Imidazoles
Oximes
Protein Kinase Inhibitors
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf
dabrafenib